1. Novo Nordisk. Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial. Press release, 23 Nov 2018. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2226789.html
2. National Institutes of Health. Landmark NIH study shows intensive blood pressure management may save lives. Press release, 11 Sep 2015. https://www.nih.gov/news-events/news-releases/landmark-nih-study-shows-intensive-blood-pressure-management-may-save-lives
3. Lower blood pressure guidelines could be lifesaving, Federal study says. New York Times 2015 12 Sep. https://www.nytimes.com/2015/09/12/health/blood-pressure-study.html
4. A Randomized Trial of Intensive versus Standard Blood-Pressure Control
5. Amarin. REDUCE-ITTM cardiovascular outcomes study of Vascepa (icosapent ethyl) capsules met primary endpoint. Press release, 24 Sep 2018. https://investor.amarincorp.com/news-releases/news-release-details/reduce-ittm-cardiovascular-outcomes-study-vascepar-icosapent.